Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France

Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France

IntroductionHeart transplant (HT) recipients have a high risk of developing severe COVID-19. Immunoglobulin G antibodies are considered to provide protective immunity and T-cell activity is thought to confer protection from severe disease. However, data on T-cell response to mRNA vaccination in a co...

Full description

Bibliographic Details
Main Authors:	Alice Casenaz, Sandrine Grosjean, Ludwig-Serge Aho-Glélé, Jean-Baptiste Bour, Christelle Auvray, Catherine Manoha
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Medicine
Subjects:	SARS-CoV-2 heart transplant recipient mRNA vaccine BNT162b2 T cell smoking
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1027708/full

Similar Items

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2022-12-01)

Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type
by: Julian Stumpf, et al.
Published: (2022-07-01)

The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
by: Sebastian Rask Hamm, et al.
Published: (2024-05-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2023-01-01)

Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant
by: Irene Cassaniti, et al.
Published: (2021-12-01)

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant
by: Valentin Letailleur, et al.
Published: (2024-12-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report
by: Harukazu Hirano, et al.
Published: (2024-12-01)

Is a single COVID-19 vaccine dose enough in convalescents ?
by: Daniele Focosi, et al.
Published: (2021-09-01)

Risk of herpes zoster following mRNA COVID-19 vaccine administration
by: Ana Florea, et al.
Published: (2023-12-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
by: Eli Magen, et al.
Published: (2022-07-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
by: Giuseppe A. Palumbo, et al.
Published: (2023-02-01)

Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
by: Tiziana Grassi, et al.
Published: (2022-11-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
by: Mazin Barry, et al.
Published: (2022-01-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children
by: Marcello Mariani, et al.
Published: (2022-08-01)

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
by: Emilie Catry, et al.
Published: (2022-07-01)

SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers
by: Maryam Golshani, et al.
Published: (2022-11-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Luigia Trabace, et al.
Published: (2022-04-01)

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination
by: Ariel Israel, et al.
Published: (2022-04-01)

Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan
by: Atsuhiko Sakamoto, et al.
Published: (2022-05-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Localized Vitiligo and Post-Inflammatory Hypopigmentation at the Injection Site of a COVID-19 mRNA Vaccine
by: Dora Mancha, et al.
Published: (2023-01-01)

Vaccine‐induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
by: Julien Favresse, et al.
Published: (2024-08-01)

Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
by: Rosalia Busà, et al.
Published: (2022-03-01)

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
by: Omid Rezahosseini, et al.
Published: (2023-01-01)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
by: Areti Tychala, et al.
Published: (2021-12-01)

Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 Vaccination
by: Sander Eens, et al.
Published: (2024-08-01)

Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report
by: Giulia Costanzo, et al.
Published: (2021-12-01)

COVID-19 mRNA BNT162b2 vaccine safety and antibodies level among healthcare workers at Centre Hospitalier du Nord
by: Rosabelle Chedid, et al.
Published: (2022-04-01)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context
by: Ivan Odak, et al.
Published: (2024-01-01)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
by: Catherine E. Raptis, et al.
Published: (2022-10-01)

Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients—Is It Related to Immunosuppression Only?
by: Paulina Nazaruk, et al.
Published: (2021-12-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
by: Stilla Bauernfeind, et al.
Published: (2022-09-01)

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines
by: Roberta Mancuso, et al.
Published: (2022-10-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
by: Lotus Leonie van den Hoogen, et al.
Published: (2022-09-01)

Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine
by: Ahmet Can Topçu, et al.
Published: (2023-04-01)